SB 932, the “Give Kids a Chance Act of 2025,” would amend the Federal Food, Drug, and Cosmetic Act to expand and clarify FDA requirements for pediatric cancer drug investigations, especially for molecularly targeted therapies. The bill would allow pediatric study obligations to be triggered not only by the drug under review, but also by certain combinations involving already-approved adult cancer drugs or standard-of-care pediatric cancer treatments, when the Secretary determines the target is relevant to pediatric cancer growth or progression. It also requires these investigations to be designed to produce clinically meaningful pediatric data on dosing, safety, and preliminary efficacy, and it directs FDA to issue guidance on implementation.
The bill also extends the rare pediatric disease priority review voucher program through September 30, 2029, and changes when the associated user fee is due. In addition, it adds reporting requirements: HHS must report to Congress on implementation efforts, and GAO must study the effectiveness of the pediatric cancer investigation requirements and the rare pediatric disease voucher program, including whether they incentivize development, speed patient access, and affect FDA workload and review priorities.
In practical terms, the bill would modify sections 505B and 529 of the Federal Food, Drug, and Cosmetic Act and affect drug and biologics sponsors seeking approval for adult and pediatric cancer products, especially companies developing targeted oncology therapies. It would also affect FDA’s review and pediatric study planning process by requiring earlier determinations about which pediatric study obligations apply and by clarifying that certain applications are not subject to both overlapping pediatric investigation pathways.
The overall sentiment reflected in the bill’s title and structure is strongly supportive of pediatric cancer research and rare disease drug development. No committee transcript or vote record is provided, so there is no recorded opposition or amendment debate in the available materials. The bill appears framed as a bipartisan effort, introduced by Senators Mullin and Bennet, suggesting broad interest in improving incentives and regulatory pathways for children’s cancer treatments.
The main points of potential contention are likely to be the scope of FDA authority, the burden on drug developers, and whether extending priority review vouchers is the best way to stimulate innovation. The bill itself anticipates these concerns by requiring GAO to study both benefits and burdens, including whether the voucher program meaningfully drives development or instead affects FDA workload and public health prioritization. Another possible issue is the bill’s expanded reach to combination products and adult-cancer drugs, which could raise questions about regulatory complexity and industry compliance costs.
The bill would amend the Federal Food, Drug, and Cosmetic Act to broaden and clarify pediatric cancer study requirements under section 505B and to extend the rare pediatric disease priority review voucher program under section 529. It would change when certain pediatric investigation obligations apply, require FDA to determine applicability earlier in the development process, and direct the agency to issue implementing guidance. It would also create new congressional reporting and GAO study requirements, affecting FDA, HHS, drug and biologics sponsors, and companies that use or receive priority review vouchers.
The available record suggests generally positive, pro-pediatric-cancer sentiment. The bill’s purpose is to accelerate development of treatments for children with cancer and rare pediatric diseases, and its bipartisan sponsorship indicates cross-party support. No committee debate or votes are included, so there is no documented opposition in the provided materials, but the bill’s built-in studies indicate awareness that the policy effects and industry burdens should be evaluated.
Likely areas of contention include whether the FDA should have expanded authority to require pediatric investigations for combination therapies and adult-cancer drugs, whether those requirements could slow development or increase costs for sponsors, and whether extending priority review vouchers until 2029 is an effective incentive. The bill also raises questions about the balance between encouraging innovation and preserving FDA review capacity, which is why it mandates GAO review of both the program’s benefits and its burdens. No specific opposing members or stakeholder positions are provided in the record.